View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 25, 2022

Sonoma signs deal to set up manufacturing centre for cell therapies

A cGMP-compliant production facility will be housed at the centre for manufacturing cell products at scale.

Sonoma Biotherapeutics has signed a lease agreement for setting up an 83,000ft² research and development (R&D) and manufacturing centre for cell therapies.

The centre, which will expand the company’s operations in Seattle, US, will aid in the R&D and manufacturing at scale its gene-modified regulatory T cell (Treg) therapy pipeline for autoimmune and inflammatory ailments.

It will also complement the company’s existing R&D enterprise in South San Francisco. 

The development and usage of innovative technologies, as well as expertise from the selection of cells and genetic modification to intelligent automation of production and information technology systems, will be part of the centre.

A cGMP-compliant production facility will be housed at the centre for manufacturing cell products at scale.

Merging this infrastructure with scientific capabilities will facilitate the company to advance well from the detection of molecular targets to in-house full-scale manufacturing for various product candidates as well as indications in Phase II studies and beyond.

The centre is also expected to provide engineering, scientific and manufacturing job opportunities in the Seattle region.

It will be established at the Seattle waterfront at 501 Elliott Avenue West, an Office Properties Income Trust-owned property. 

The RMR Group is redeveloping the property into Unison Elliott Bay.

Sonoma Biotherapeutics chief technical officer Heidi Hagen said: “Sonoma Bio is at the forefront of developing Treg therapies to treat autoimmune and inflammatory diseases by restoring balance to the immune system, and we are establishing robust and nimble infrastructure from end-to-end to deliver these cellular products. 

“Through the integration of our R&D engine with next-generation process development and cell therapy production tools, we will have the ability to quickly and efficiently deliver potentially transformative therapies to patients in need.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology